Clinical Trial Update: Iptacopan in Patients With ANCA Associated Vasculitis [Phase 2]

View source ↗

Summary

Iptacopan is being studied in a Phase 2 clinical trial for ANCA-associated vasculitis. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING